Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure.
about
Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and DifferencesPharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers?Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animalsEffects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure ratsAngiotensin-II-induced Muscle Wasting is Mediated by 25-Hydroxycholesterol via GSK3β Signaling Pathway.Bone and muscle loss after spinal cord injury: organ interactions.Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration.Mitochondria-derived superoxide links to tourniquet-induced apoptosis in mouse skeletal muscleDown-regulation of MyoD gene expression in rat diaphragm muscle with heart failure.Understanding results of trials in heart failure with preserved ejection fraction: remembering forgotten lessons and enduring principlesSkeletal muscle abnormalities in chronic heart failure patients: relation to exercise capacity and therapeutic implications.Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice.Diaphragm dysfunction in heart failure is accompanied by increases in neutral sphingomyelinase activity and ceramide contentThe Role of Congestion in Cardiorenal Syndrome Type 2: New Pathophysiological Insights into an Experimental Model of Heart FailureDrug target identification using network analysis: Taking active components in Sini decoction as an example.Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexiaExercise intolerance in chronic heart failure: mechanisms and therapies. Part I.Cellular apoptosis in the cardiorenal axis.Effects of Astragaloside IV on heart failure in rats.Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production.Effect of thalidomide on the skeletal muscle in experimental heart failure.L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure.Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure.Changes in skeletal muscle SR Ca2+ pump in congestive heart failure due to myocardial infarction are prevented by angiotensin II blockade.Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia.High saturated-fat diet induces apoptosis in rat enterocytes and blunts GIP and insulin-secretive response to oral glucose load.The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).Data on the stem cells paracrine effects on apoptosis and cytokine milieu in an experimental model of cardiorenal syndrome type II
P2860
Q26767412-4D59A64F-C666-433F-B44D-BD72BC64F4EAQ26775758-00F67A91-0551-43AB-9655-81086FE67E4CQ28570699-8384EBD0-1579-4EAE-A24E-D2A6B55D4CB2Q33654750-C37C3E86-6E34-4B92-8CB0-E860BA387C08Q33809770-8434B7B9-B58C-4739-9F20-EAE4774E4A36Q34148869-17E3F003-EF2C-42F2-B83F-F9AD6E10200AQ34248966-786237DC-5F3F-4919-A02B-6B358344B514Q34389593-F1142FEC-B5A1-4E41-BD58-8EB3C99823FEQ34656253-B3721EC0-854C-486F-A2EA-C21471478CE7Q34999474-22BE59B3-6A31-4EE5-A2FC-233EACECB357Q35162695-62880BD1-EBF3-44DE-8A45-B76E95D6F9FDQ35750099-342D3112-5AE4-4E8C-BBD4-239C20AAD7BDQ36306227-4039780A-4EAB-4F55-9008-A84E07F5A4ECQ36423145-9879F309-9C3F-4440-B80F-CC3D51DE4C4DQ36814771-1227BB52-8282-4CC3-A616-4521FB771A5BQ37138465-7F3F24E8-399B-425F-A265-E253D8CE2003Q37832481-D065111B-6CB4-4B34-82AD-B104EA0FEE3EQ38725113-92C6882B-02BB-4F08-BF4F-D5CC5A6B9205Q41975237-260BE4AA-6B11-440C-9AD4-622B4C24B8AFQ43903158-5070E258-65D1-4608-A04A-3C1D0788D43CQ44094091-EB63EA72-EF11-4ACD-A0AA-5EEAD530183AQ44101881-33F15EAF-7C4C-417F-9D7B-E148161DA3D9Q44588532-F3406D42-53A2-4A55-BD15-28F34D2A3CF7Q45076005-A48BC95B-E136-4BE6-99E3-B29BD90B811CQ46359228-9474FE87-881C-4FCF-8AFE-4F1618159B39Q46746644-320D8105-1390-414A-AFD4-FDF0555629EAQ47851502-32A3A83D-96D2-46EF-B5D2-693AD83328D7Q59129643-87390885-0BB7-4F28-B741-27B32D4B100B
P2860
Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Beneficial effects on skeletal ...... in experimental heart failure.
@en
Beneficial effects on skeletal ...... in experimental heart failure.
@nl
type
label
Beneficial effects on skeletal ...... in experimental heart failure.
@en
Beneficial effects on skeletal ...... in experimental heart failure.
@nl
prefLabel
Beneficial effects on skeletal ...... in experimental heart failure.
@en
Beneficial effects on skeletal ...... in experimental heart failure.
@nl
P2093
P1433
P1476
Beneficial effects on skeletal ...... in experimental heart failure.
@en
P2093
A Angelini
G Battista Ambrosio
L Dalla Libera
P304
P356
10.1161/01.CIR.103.17.2195
P407
P577
2001-05-01T00:00:00Z